Caxton Associates LP Vertex Pharmaceuticals Inc Transaction History

Caxton Associates LP

$2.65 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$392.81 - $485.53 $891,285 - $1.1 Million	-2,269 Reduced 39.33%	3,500 $1.64 Million
Q1 2024 May 15, 2024	SELL	$407.69 - $446.08 $29 Million - $31.7 Million	-71,034 Reduced 92.49%	5,769 $2.41 Million
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $24.6 Million - $29.4 Million	71,624 Added 1382.97%	76,803 $31.3 Million
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $1.37 Million - $1.47 Million	4,060 Added 362.82%	5,179 $1.8 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $351,835 - $393,787	1,119 New	1,119 $393,000
Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $352,056 - $396,063	-1,232 Reduced 24.36%	3,826 $1.1 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $1.08 Million - $1.2 Million	3,943 Added 353.63%	5,058 $1.46 Million
Q2 2022 Aug 15, 2022	BUY	$234.96 - $292.55 $261,980 - $326,193	1,115 New	1,115 $314,000
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $449,704 - $530,030	-2,031 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $424,115 - $535,386	-2,396 Reduced 54.12%	2,031 $446,000
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $803,013 - $898,636	4,427 New	4,427 $803,000
Q4 2020 Feb 16, 2021	SELL	$207.01 - $276.09 $612,956 - $817,502	-2,961 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$255.65 - $303.1 $149,299 - $177,010	-584 Reduced 16.47%	2,961 $806,000
Q2 2020 Aug 14, 2020	BUY	$225.48 - $295.8 $535,515 - $702,525	2,375 Added 202.99%	3,545 $1.03 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $373,969 - $463,900	-1,872 Reduced 61.54%	1,170 $278,000
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $507,131 - $681,134	3,042 New	3,042 $666,000
Q4 2017 Feb 14, 2018	SELL	$137.28 - $155.55 $274,560 - $311,100	-2,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $296,260 - $324,480	2,000	2,000 $304,000

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

Capital World Investors Los Angeles, CA

26.8M
Shares

$12.5 Billion
1.99% of portfolio
Vanguard Group Inc Valley Forge, PA

23.2M
Shares

$10.8 Billion
0.2% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$9.9 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.8M
Shares

$5.49 Billion
0.23% of portfolio
Capital Research Global Investors Los Angeles, CA

9M
Shares

$4.18 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Caxton Associates LP with notifications on news.

Account